Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality
- 31 August 2006
- journal article
- Published by Elsevier BV in Urology
- Vol. 68 (2), 342-347
- https://doi.org/10.1016/j.urology.2006.02.030
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Evidence to Support a Continued Stage Migration and Decrease in Prostate Cancer Specific MortalityJournal of Urology, 2006
- Predictors of Prostate Cancer–Specific Mortality After Radical Prostatectomy or Radiation TherapyJournal of Clinical Oncology, 2005
- BICALUTAMIDE 150 MG IN ADDITION TO STANDARD CARE IN PATIENTS WITH LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER: RESULTS FROM THE SECOND ANALYSIS OF THE EARLY PROSTATE CANCER PROGRAM AT MEDIAN FOLLOWUP OF 5.4 YEARSJournal of Urology, 2004
- The science of early detectionUrologic Oncology: Seminars and Original Investigations, 2004
- Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per MilliliterNew England Journal of Medicine, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Time Course and Predictors of Symptoms After Primary Prostate Cancer TherapyJournal of Clinical Oncology, 2003
- Cancer-Specific Mortality After Surgery or Radiation for Patients With Clinically Localized Prostate Cancer Managed During the Prostate-Specific Antigen EraJournal of Clinical Oncology, 2003
- ERA SPECIFIC BIOCHEMICAL RECURRENCE-FREE SURVIVAL FOLLOWING RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCERJournal of Urology, 2001
- On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology DataJournal of the American Statistical Association, 1993